Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK 285

Known as: EGFR/HER2 Kinase Inhibitor TAK-285, TAK-285, TAK285 
An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The human epidermal growth factor receptor (HER) family plays a major role in cancer cell proliferation. Overexpression of these… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
SummaryIntroduction This phase 1 study assessed safety, maximum tolerated dose (MTD), pharmacokinetics, cerebrospinal fluid (CSF… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors… Expand
  • figure 1
  • figure 3
  • table 1
  • figure 4
  • figure 5
Is this relevant?
2013
2013
The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Background:This phase I first-in-human study was conducted in Japanese patients to investigate the safety, pharmacokinetics (PKs… Expand
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2012
2012
TAK-285, an investigational, orally active HER2/EGRF inhibitor is in clinical development for potential use in HER2 over… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is… Expand
Is this relevant?
2011
2011
Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been… Expand
Is this relevant?
2011
2011
2538 Background: TAK-285 is an investigational, orally active, dual HER2/EGFR inhibitor with antitumor activity in mouse… Expand
Is this relevant?
2009
2009
Background: Approximately one third of patients with HER2-overexpressing (HER2+) metastatic breast cancer develop brain… Expand
Is this relevant?